CY1116692T1 - Πυρρολοπυριδινες ως αναστολεις κινασης - Google Patents

Πυρρολοπυριδινες ως αναστολεις κινασης

Info

Publication number
CY1116692T1
CY1116692T1 CY20151100812T CY151100812T CY1116692T1 CY 1116692 T1 CY1116692 T1 CY 1116692T1 CY 20151100812 T CY20151100812 T CY 20151100812T CY 151100812 T CY151100812 T CY 151100812T CY 1116692 T1 CY1116692 T1 CY 1116692T1
Authority
CY
Cyprus
Prior art keywords
pyrrolopyridines
suspensions
movement
compounds
formula
Prior art date
Application number
CY20151100812T
Other languages
English (en)
Inventor
Huerou Yvan Le
James F Blake
Indrani W Gunwardana
Peter Mohr
Eli M Wallace
Bin Wang
Mark Chicarelli
Michael Lyon
Original Assignee
Array Biopharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40810786&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1116692(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma, Inc. filed Critical Array Biopharma, Inc.
Publication of CY1116692T1 publication Critical patent/CY1116692T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

Ενώσεις του Τύπου (I) είναι χρήσιμες για αναστολή CHK2 ή/και CHK2. Μέθοδοι χρήσης ενώσεων του Τύπου (I) και στερεοϊσομερών και φαρμακευτικώς αποδεκτών αλάτων αυτών, για in vitro, in situ και in vivo διάγνωση, πρόληψη ή θεραπεία τέτοιων διαταραχών σε κύτταρα θηλαστικού, ή συναφείς παθολογικές καταστάσεις αποκαλύπτονται.
CY20151100812T 2008-05-13 2015-09-16 Πυρρολοπυριδινες ως αναστολεις κινασης CY1116692T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5292608P 2008-05-13 2008-05-13
EP09747404.3A EP2307409B1 (en) 2008-05-13 2009-05-13 Pyrrolopyridines as kinase inhibitors

Publications (1)

Publication Number Publication Date
CY1116692T1 true CY1116692T1 (el) 2017-03-15

Family

ID=40810786

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100812T CY1116692T1 (el) 2008-05-13 2015-09-16 Πυρρολοπυριδινες ως αναστολεις κινασης

Country Status (30)

Country Link
US (6) US8178131B2 (el)
EP (2) EP2307409B1 (el)
JP (2) JP5703212B2 (el)
KR (2) KR101657856B1 (el)
CN (3) CN102089307B (el)
AR (1) AR071717A1 (el)
AU (1) AU2009246402B2 (el)
BR (1) BRPI0913580B8 (el)
CA (1) CA2724262C (el)
CL (1) CL2009001152A1 (el)
CO (1) CO6321244A2 (el)
CR (1) CR11803A (el)
CY (1) CY1116692T1 (el)
DK (1) DK2307409T3 (el)
ES (1) ES2552643T3 (el)
HK (2) HK1152035A1 (el)
HR (1) HRP20151018T1 (el)
HU (1) HUE026160T2 (el)
IL (1) IL209258A (el)
MX (1) MX2010012449A (el)
NZ (1) NZ589318A (el)
PH (1) PH12013501779A1 (el)
PL (1) PL2307409T3 (el)
PT (1) PT2307409E (el)
RS (1) RS54358B1 (el)
RU (1) RU2517194C2 (el)
SI (1) SI2307409T1 (el)
TW (2) TWI554512B (el)
UA (1) UA111933C2 (el)
WO (1) WO2009140320A1 (el)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2711614A1 (en) 2008-01-08 2009-07-16 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
ES2392014T3 (es) 2008-01-09 2012-12-03 Array Biopharma, Inc. Pirazolopiridinas como inhibidores de la cinasa
JP2009256298A (ja) * 2008-03-26 2009-11-05 Sumitomo Chemical Co Ltd ピペリジン−３−イルカーバメート化合物の光学分割方法およびその中間体
CL2009001152A1 (es) 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
US8481557B2 (en) 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
CA2758300C (en) * 2009-04-11 2017-07-25 Array Biopharma Inc. Checkpoint kinase 1 inhibitors for potentiating dna damaging agents
TWI466885B (zh) 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
WO2011029043A1 (en) * 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Heteroaryl btk inhibitors
CN103119045B (zh) 2010-08-20 2016-02-17 和记黄埔医药（上海）有限公司 吡咯并嘧啶化合物及其用途
BR112013011918A2 (pt) * 2010-11-16 2020-08-25 Array Biopharma, Inc inibidor de chk1, composição farmacêutica e kit compreendendo o referido inibidor
MX339899B (es) 2011-02-25 2016-06-16 Array Biopharma Inc Compuestos de triazolopiridina como inhibidores de pim cinasa.
MX2013012661A (es) 2011-04-29 2014-03-27 Amgen Inc Compuestos de piridazina biciclicos como inhibidores pim.
GB201201566D0 (en) * 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds
BR112014026367A2 (pt) * 2012-04-23 2017-06-27 Genentech Inc 5-bromo-4-cloro-3-nitro-1h-pirrol[2,3-b]piridina e seu processo
KR20160104612A (ko) 2013-07-26 2016-09-05 업데이트 파마 인코포레이트 비산트렌의 치료 효과 개선용 조성물
KR102325163B1 (ko) * 2013-08-22 2021-11-11 제넨테크, 인크. 화합물의 제조 방법
WO2015027090A1 (en) * 2013-08-22 2015-02-26 Genentech, Inc. Intermediates and processes for preparing compounds
EP3412668B1 (en) 2013-09-25 2020-02-05 Vertex Pharmaceuticals Incorporated A selective inhibitor of phosphatidylinositol 3-kinase-gamma
WO2015154064A2 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
AR101106A1 (es) 2014-07-02 2016-11-23 Pharmacyclics Llc Inhibidores de tirosina quinasa de bruton
MA41599A (fr) * 2015-02-26 2018-01-02 Array Biopharma Inc Formes cristallines d'un composé pyrrolopyridine
CN107708414B (zh) 2015-06-30 2022-02-25 首尔伟傲世有限公司 适用紫外线发光二极管的捕虫器
US20170119766A1 (en) * 2015-11-04 2017-05-04 Merck Patent Gmbh Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity
JP2018538330A (ja) * 2015-12-22 2018-12-27 ヴァイティー ファーマシューティカルズ，インコーポレイテッド ｍｅｎｉｎ−ＭＬＬ相互作用の阻害剤
KR20220123727A (ko) 2016-06-10 2022-09-08 비타이 파마슈티컬즈, 엘엘씨 메닌-mll 상호 작용의 억제제
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
TW202014408A (zh) 2018-07-03 2020-04-16 美商Ｉｆｍ Ｄｕｅ有限公司 用於治療與sting活性相關之病症的化合物及組合物
CN108912032A (zh) * 2018-08-13 2018-11-30 南通大学 一种（3s，4r）-4-甲基吡咯烷-3-基氨基甲醇叔丁酯盐酸盐的化学合成方法
CN109053526A (zh) * 2018-08-13 2018-12-21 南通大学 一种（3r，4s）-4-甲基吡咯烷-3-基氨基甲酸叔丁酯盐酸盐的化学合成方法
TW202043198A (zh) 2019-01-17 2020-12-01 美商Ｉｆｍ Ｄｕｅ有限公司 用於治療與sting活性相關之病況的化合物及組合物
EP4182310A1 (en) 2020-07-15 2023-05-24 IFM Due, Inc. Compounds and compositions for treating conditions associated with sting activity
AR125866A1 (es) 2021-05-14 2023-08-23 Syndax Pharmaceuticals Inc Inhibidores de la interacción de menina-mll

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU689809B2 (en) * 1993-10-14 1998-04-09 Abbott Laboratories Quinolizinone type compounds
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
WO2001058869A2 (en) 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
WO2001079198A1 (en) 2000-04-18 2001-10-25 Agouron Pharmaceuticals, Inc. Pyrazoles for inhibiting protein kinase
US7115741B2 (en) 2001-09-06 2006-10-03 Levy Daniel E 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds
WO2003028724A1 (en) * 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
US6797825B2 (en) * 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
WO2004014910A1 (en) 2002-08-07 2004-02-19 Mitsubishi Pharma Corporation Dihydropyrazolopyridine compounds
US20050256157A1 (en) * 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
AR042667A1 (es) 2002-12-26 2005-06-29 Taisho Pharmaceutical Co Ltd Derivados de pirrolopirimidina y pirrolopiridina sustituidos con un grupo amino ciclico
WO2004081008A1 (en) 2003-03-14 2004-09-23 Astrazeneca Ab Novel fused triazolones and the uses thereof
GB0308208D0 (en) * 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
GB0330042D0 (en) * 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
GB0330043D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
KR20070002081A (ko) * 2004-04-02 2007-01-04 버텍스 파마슈티칼스 인코포레이티드 Ｒｏｃｋ 및 기타 단백질 키나아제의 억제제로서 유용한아자인돌
TWI380816B (zh) * 2004-04-13 2013-01-01 Synta Pharmaceuticals Corp 抑制介白素-１２（ｉｌ-１２）生成之二鹽抑制劑
GB0409080D0 (en) 2004-04-23 2004-05-26 Biofocus Discovery Ltd Compounds which interact with protein kinases
JP2007161585A (ja) 2004-06-25 2007-06-28 Taisho Pharmaceut Co Ltd 環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
EP1869052A1 (en) 2005-04-06 2007-12-26 AstraZeneca AB Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
MX2007014619A (es) * 2005-05-20 2009-02-13 Vertex Pharma Pirrolopiridinas de utilidad como inhibidores de proteina quinasa.
CN101253166B (zh) * 2005-08-30 2013-07-10 旭化成制药株式会社 磺酰胺化合物
US20070082900A1 (en) * 2005-10-06 2007-04-12 Schering Corporation Methods for inhibiting protein kinases
AR056206A1 (es) 2005-10-06 2007-09-26 Schering Corp Pirazolpirimidinas como inhibidores de protein quinasas
DK2348023T5 (da) 2005-12-13 2017-05-15 Incyte Holdings Corp Heteroaryl-substituerede pyrrolo[2,3-b]pyridiner og pyrrolo[2,3-b]pyrimidiner som Janus-kinase-inhibitorer
US20070208053A1 (en) 2006-01-19 2007-09-06 Arnold Lee D Fused heterobicyclic kinase inhibitors
DE102006005179A1 (de) 2006-02-06 2007-08-09 Merck Patent Gmbh Aminoindazolderivate
DE102006005180A1 (de) 2006-02-06 2007-08-09 Merck Patent Gmbh Indazol-heteroaryl-derivate
WO2007125310A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical combinations of pk inhibitors and other active agents
JP2009536161A (ja) 2006-04-25 2009-10-08 アステックス、セラピューティックス、リミテッド 医薬化合物
EP2043655A2 (en) 2006-04-25 2009-04-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
WO2008075007A1 (en) 2006-12-21 2008-06-26 Cancer Research Technology Limited Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents
JP5330274B2 (ja) 2007-03-01 2013-10-30 ノバルティス アーゲー Ｐｉｍキナーゼ阻害剤およびその使用方法
EP2170886A1 (en) * 2007-07-02 2010-04-07 Cancer Research Technology Limited 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors
JP2011503084A (ja) 2007-11-07 2011-01-27 シェーリング コーポレイション 新規の細胞周期チェックポイント調節剤およびこれらの調節剤とチェックポイント阻害剤との併用
CA2711614A1 (en) * 2008-01-08 2009-07-16 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
ES2392014T3 (es) * 2008-01-09 2012-12-03 Array Biopharma, Inc. Pirazolopiridinas como inhibidores de la cinasa
CL2009001152A1 (es) 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
US8481557B2 (en) * 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
US20140221370A1 (en) 2010-07-09 2014-08-07 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
BR112013011918A2 (pt) 2010-11-16 2020-08-25 Array Biopharma, Inc inibidor de chk1, composição farmacêutica e kit compreendendo o referido inibidor

Also Published As

Publication number Publication date
CA2724262A1 (en) 2009-11-19
US20130045286A1 (en) 2013-02-21
HRP20151018T1 (hr) 2015-10-23
KR20110008102A (ko) 2011-01-25
US20140243520A1 (en) 2014-08-28
JP2015098482A (ja) 2015-05-28
KR20140093266A (ko) 2014-07-25
IL209258A0 (en) 2011-01-31
PH12013501779B1 (en) 2014-08-27
JP5703212B2 (ja) 2015-04-15
WO2009140320A1 (en) 2009-11-19
UA111933C2 (uk) 2016-07-11
DK2307409T3 (en) 2015-09-21
EP2307409A1 (en) 2011-04-13
BRPI0913580B1 (pt) 2020-03-10
IL209258A (en) 2017-01-31
HUE026160T2 (en) 2016-05-30
TW201529573A (zh) 2015-08-01
CN104926810A (zh) 2015-09-23
RU2010150786A (ru) 2012-06-20
CR11803A (es) 2011-02-11
SI2307409T1 (sl) 2015-11-30
US20140100369A1 (en) 2014-04-10
US8178131B2 (en) 2012-05-15
EP2990407A1 (en) 2016-03-02
US9365568B2 (en) 2016-06-14
AU2009246402A1 (en) 2009-11-19
BRPI0913580B8 (pt) 2021-05-25
EP2307409B1 (en) 2015-08-12
PH12013501779A1 (en) 2014-08-27
US8981085B2 (en) 2015-03-17
NZ589318A (en) 2011-06-30
CN102089307B (zh) 2015-07-01
US20160368916A1 (en) 2016-12-22
PT2307409E (pt) 2015-11-04
CL2009001152A1 (es) 2009-10-16
US8758830B2 (en) 2014-06-24
TWI458727B (zh) 2014-11-01
BRPI0913580A2 (pt) 2015-10-20
US8545897B2 (en) 2013-10-01
AR071717A1 (es) 2010-07-07
CO6321244A2 (es) 2011-09-20
ES2552643T3 (es) 2015-12-01
PL2307409T3 (pl) 2016-01-29
CN102089307A (zh) 2011-06-08
JP2011520896A (ja) 2011-07-21
TWI554512B (zh) 2016-10-21
US20110070317A1 (en) 2011-03-24
KR101643426B1 (ko) 2016-07-27
US9969727B2 (en) 2018-05-15
US20150322061A1 (en) 2015-11-12
HK1219950A1 (zh) 2017-04-21
AU2009246402B2 (en) 2013-05-23
KR101657856B1 (ko) 2016-09-19
EP2990407B1 (en) 2019-10-16
CN104926810B (zh) 2019-02-19
RU2517194C2 (ru) 2014-05-27
CN109942575A (zh) 2019-06-28
MX2010012449A (es) 2011-05-25
HK1152035A1 (en) 2012-02-17
RS54358B1 (en) 2016-04-28
TW201002707A (en) 2010-01-16
CA2724262C (en) 2017-08-15

Similar Documents

Publication Publication Date Title
CY1116692T1 (el) Πυρρολοπυριδινες ως αναστολεις κινασης
CY1120172T1 (el) Αναστολεις κινασων σερινης/θρεονινης
CY1126122T1 (el) Αναστολεις πρωτεϊνικης φωσφατασης της τυροσινης
CY1118129T1 (el) 5-αλκυνυλ-πυριμιδινες
ECSP10010510A (es) Compuestos del inhibidor de raf y métodos de uso de los mismos
ECSP10010507A (es) Pirazolo (3, 4-b) piridina inhibidores de raf
CY1118452T1 (el) Ενωσεις και συνθεσεις ως αναστολεις πρωτεϊνικης κινασης
CY1117097T1 (el) Ενωσεις ετεροαρυλο πυριδονης και αζα-πυριδονης ως αναστολεις της δρασης της βτκ
CY1116628T1 (el) Ενωσεις σπειρο-οξινδολιου και χρηση αυτων ως θεραπευτικοι παραγοντες
ECSP12012326A (es) Derivados de aminopirimidina como moduladores de la lrrk2
CY1116681T1 (el) 5-ανιλινοϊμιδαζοπυριδινες και μεθοδοι χρησης
CY1113924T1 (el) Ενωσεις καρβαζολης και θεραπευτικες χρησεις των ενωσεων
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
PL1891029T3 (pl) Związki organiczne do leczenia stanów zapalnych lub alergicznych
ECSP088791A (es) Compuestos pirazólicos heterobicíclicos y métodos de uso.
PH12013502369A1 (en) Diazacarbazoles and methods of use
MY160349A (en) Pyridone and aza-pyridone compounds and methods of use
MX338504B (es) Combinaciones de compuestos inhibidores de fosfoinosituro 3-cinasa y agentes quimioterapeuticos, y metodos de uso.
SG178899A1 (en) Raf inhibitor compounds and methods of use thereof
CY1116452T1 (el) Θετικοι αλλοστερικοι ρυθμιστες μ1 υποδοχεα του τυπου πυρανυλ αρυλ μεθυλ βενζοκιναζολινονης
DOP2011000134A (es) Lactamas como inhibidores de beta secretasa
EA200970936A1 (ru) СОЕДИНЕНИЯ ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3K-АЛЬФА ДЛЯ ЛЕЧЕНИЯ РАКА
CY1114140T1 (el) Ενωσεις 4-πυριδινονης και η χρηση αυτων για τον καρκινο
MX2012006822A (es) 1,7-diazacarbazoles y metodos de uso.